Cargando…

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

BACKGROUND: An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune cell-derived markers and clinical predictors such as serum lactate dehydrogenase (LDH) and cutaneous adverse events, have already...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Yoshio, Kitano, Shigehisa, Takahashi, Akira, Tsutsumida, Arata, Namikawa, Kenjiro, Tanese, Keiji, Abe, Takayuki, Funakoshi, Takeru, Yamamoto, Noboru, Amagai, Masayuki, Yamazaki, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363594/ https://www.ncbi.nlm.nih.gov/pubmed/27764805 http://dx.doi.org/10.18632/oncotarget.12677

Ejemplares similares

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)
por: Yamazaki, Naoya, et al.
Publicado: (2021)

Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol
por: Hirai, Ikuko, et al.
Publicado: (2021)

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2018)

Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer
por: Tanese, Keiji, et al.
Publicado: (2019)

A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol)
por: Oashi, Kohei, et al.
Publicado: (2020)

Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
por: Ishii, Maki, et al.
Publicado: (2020)

BRAF V600 mutations and pathological features in Japanese melanoma patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
por: Namikawa, Kenjiro, et al.
Publicado: (2017)

Targeted Therapy and Immunotherapy for Melanoma in Japan
por: Namikawa, Kenjiro, et al.
Publicado: (2019)

Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol)
por: Tanaka, Kiyo, et al.
Publicado: (2019)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
por: Kimbara, Shiro, et al.
Publicado: (2018)

Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab
por: Omata, Wataru, et al.
Publicado: (2022)

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2019)

Periostin Is a Key Niche Component for Wound Metastasis of Melanoma
por: Fukuda, Keitaro, et al.
Publicado: (2015)

Intramedullary spinal cord metastasis of malignant melanoma:Two cases with rim signs in contrast-enhanced magnetic resonance imaging: A case report
por: Mizuta, Haruki, et al.
Publicado: (2021)

Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses
por: Omata, W., et al.
Publicado: (2017)

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports
por: Yoshino, Koji, et al.
Publicado: (2019)

Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post‐marketing surveillance
por: Uhara, Hisashi, et al.
Publicado: (2022)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Post-Immunotherapy Robotic-Assisted Resection for Primary Anorectal Melanoma: A Case Report
por: Tsutsui, Keita, et al.
Publicado: (2022)

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
por: Fujimura, Taku, et al.
Publicado: (2019)

Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Uhara, Hisashi, et al.
Publicado: (2021)

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases
por: Ishiguro, Akihiro, et al.
Publicado: (2022)

Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma
por: Takai, Erina, et al.
Publicado: (2021)

Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2019)

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
por: Ozaki, Yukinori, et al.
Publicado: (2017)

Rituximab therapy for intractable pemphigus: A multicenter, open‐label, single‐arm, prospective study of 20 Japanese patients
por: Yamagami, Jun, et al.
Publicado: (2022)

Superficial Penile Leiomyosarcoma Mimicking a Benign Tumor
por: Haruki, Mizuta, et al.
Publicado: (2021)

Stratification of atopic dermatitis patients by patterns of response to proactive therapy with topical tacrolimus: low serum IgE levels and inadequately controlled disease activity at the start of treatment predict its failure
por: Kasai, Hiroko, et al.
Publicado: (2021)

Comparison of basophil activation test and lymphocyte transformation test as diagnostic assays for drug hypersensitivity
por: Adachi, Takeya, et al.
Publicado: (2014)

Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
por: Fujimura, Taku, et al.
Publicado: (2020)

Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
por: Fujimura, Taku, et al.
Publicado: (2018)

Epidemiology of skin cancer based on Japan's National Cancer Registry 2016–2017
por: Ogata, Dai, et al.
Publicado: (2023)

Life-threatening rocuronium-induced anaphylactic shock without cutaneous manifestations successfully reversed with sugammadex: a case report
por: Takise, Yoshiaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6de7ccor2p0s8ua967ghh01im6